Drug Therapy: Oral Phosphate Binders in Patients with Kidney Failure.

被引：255
作者：
Tonelli, Marcello [1 ,2 ]
Pannu, Neesh [1 ,3 ]
Manns, Braden [4 ,5 ]
机构：
[1] Univ Alberta, Dept Med, Edmonton, AB, Canada
[2] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB, Canada
[3] Univ Alberta, Div Crit Care Med, Edmonton, AB, Canada
[4] Univ Calgary, Dept Med, Calgary, AB, Canada
[5] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2010年 / 362卷 / 14期
基金：
加拿大健康研究院;
关键词：
CORONARY-ARTERY CALCIFICATION; CHRONIC-HEMODIALYSIS PATIENTS; CHRONIC-RENAL-FAILURE; LANTHANUM CARBONATE; CALCIUM-CARBONATE; SEVELAMER-HYDROCHLORIDE; DIALYSIS PATIENTS; MAGNESIUM CARBONATE; ALUMINUM-HYDROXIDE; SERUM PHOSPHORUS;
D O I：
10.1056/NEJMra0912522
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hyperphosphatemia, which is nearly universal in kidney failure, is accompanied by low serum levels of vitamin D and hypocalcemia. Without treatment, severe secondary hyperparathyroidism occurs, which may result in painful fractures, brown tumors, and generalized osteopenia. This article reviews the rationale for treatment with oral phosphate binders, discusses evidence supporting the use of available agents, and suggests an approach for clinical practice. Copyright © 2010 Massachusetts Medical Society. All rights reserved.
引用
收藏
页码：1312 / 1324
页数：13
相关论文
共 109 条
  • [1] Lanthanum carbonate (Fosrenol®):: a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients
    Albaaj, F
    Hutchison, AJ
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (09) : 1091 - 1096
  • [2] Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients
    Almirall, J
    Lopez, TS
    Vallve, M
    Ruiz, A
    Llibre, J
    Betriu, A
    [J]. NEPHRON CLINICAL PRACTICE, 2004, 97 (01): : C17 - C22
  • [3] Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density
    Asmus, HG
    Braun, J
    Krause, R
    Brunkhorst, R
    Holzer, H
    Schulz, W
    Neumayer, HH
    Raggi, P
    Bommer, J
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (08) : 1653 - 1661
  • [4] Phosphate Binder Impact on Bone Remodeling and Coronary Calcification - Results from the BRiC Study
    Barreto, Daniela Veit
    Barreto, Fellype de Carvalho
    de Carvalho, Aluizio Barbosa
    Cuppari, Lilian
    Draibe, Sergio Antonio
    Dalboni, Maria Aparecida
    Affonso Moyses, Rosa Maria
    Neves, Katia Rodrigues
    Jorgetti, Vanda
    Miname, Marcio
    Santos, Raul D.
    Fernandes Canziani, Maria Eugenia
    [J]. NEPHRON CLINICAL PRACTICE, 2008, 110 (04): : C273 - C283
  • [5] Niacin and related compounds for treating hyperphosphatemia in dialysis patients
    Berns, Jeffrey S.
    [J]. SEMINARS IN DIALYSIS, 2008, 21 (03) : 203 - 205
  • [6] Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients
    Block, G. A.
    Raggi, P.
    Bellasi, A.
    Kooienga, L.
    Spiegel, D. M.
    [J]. KIDNEY INTERNATIONAL, 2007, 71 (05) : 438 - 441
  • [7] Mineral metabolism, mortality, and morbidity in maintenance hemodialysis
    Block, GA
    Klassen, PS
    Lazarus, JM
    Ofsthun, N
    Lowrie, EG
    Chertow, GM
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08): : 2208 - 2218
  • [8] Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
    Block, GA
    Hulbert-Shearon, TE
    Levin, NW
    Port, FK
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) : 607 - 617
  • [9] Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis
    Block, GA
    Spiegel, DM
    Ehrlich, J
    Mehta, R
    Lindbergh, J
    Dreisbach, A
    Raggi, P
    [J]. KIDNEY INTERNATIONAL, 2005, 68 (04) : 1815 - 1824
  • [10] What have we learnt about the regulation of phosphate metabolism?
    Blumsohn, A
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2004, 13 (04) : 397 - 401
12345678910